Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 449

1.

The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.

Gayarre J, Kamieniak MM, Cazorla-Jiménez A, Muñoz-Repeto I, Borrego S, García-Donas J, Hernando S, Robles-Díaz L, García-Bueno JM, Ramón Y Cajal T, Hernández-Agudo E, Heredia Soto V, Márquez-Rodas I, Echarri MJ, Lacambra-Calvet C, Sáez R, Cusidó M, Redondo A, Paz-Ares L, Hardisson D, Mendiola M, Palacios J, Benítez J, García MJ.

J Gynecol Oncol. 2016 Jan;27(1):e7. doi: 10.3802/jgo.2016.27.e7. Epub 2015 Nov 27.

2.

ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.

Hedditch EL, Gao B, Russell AJ, Lu Y, Emmanuel C, Beesley J, Johnatty SE, Chen X, Harnett P, George J; Australian Ovarian Cancer Study Group, Williams RT, Flemming C, Lambrechts D, Despierre E, Lambrechts S, Vergote I, Karlan B, Lester J, Orsulic S, Walsh C, Fasching P, Beckmann MW, Ekici AB, Hein A, Matsuo K, Hosono S, Nakanishi T, Yatabe Y, Pejovic T, Bean Y, Heitz F, Harter P, du Bois A, Schwaab I, Hogdall E, Kjaer SK, Jensen A, Hogdall C, Lundvall L, Engelholm SA, Brown B, Flanagan J, Metcalf MD, Siddiqui N, Sellers T, Fridley B, Cunningham J, Schildkraut J, Iversen E, Weber RP, Berchuck A, Goode E, Bowtell DD, Chenevix-Trench G, deFazio A, Norris MD, MacGregor S, Haber M, Henderson MJ.

J Natl Cancer Inst. 2014 Jun 23;106(7). pii: dju149. doi: 10.1093/jnci/dju149. Print 2014 Jul.

3.

FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.

Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D'Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F, Ravaggi A.

J Exp Clin Cancer Res. 2017 May 8;36(1):63. doi: 10.1186/s13046-017-0536-y.

4.

[Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].

Mao YN, Zeng LX, Li YH, Liu YZ, Wu JY, Li L, Wang Q.

Zhonghua Fu Chan Ke Za Zhi. 2017 Oct 25;52(10):687-696. doi: 10.3760/cma.j.issn.0529-567X.2017.10.008. Chinese.

PMID:
29060967
5.

POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.

Karlan BY, Dering J, Walsh C, Orsulic S, Lester J, Anderson LA, Ginther CL, Fejzo M, Slamon D.

Gynecol Oncol. 2014 Feb;132(2):334-42. doi: 10.1016/j.ygyno.2013.12.021. Epub 2013 Dec 22.

PMID:
24368280
6.

A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.

Koti M, Siu A, Clément I, Bidarimath M, Turashvili G, Edwards A, Rahimi K, Mes-Masson AM, Squire JA.

Br J Cancer. 2015 Mar 31;112(7):1215-22. doi: 10.1038/bjc.2015.81. Erratum in: Br J Cancer. 2015 Dec 22;113(12):1746. Masson, A-M M [corrected to Mes-Masson, A-M].

7.

Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.

Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, Xue F, Sood AK, Zhang W.

J Natl Cancer Inst. 2015 May 20;107(7). pii: djv108. doi: 10.1093/jnci/djv108. Print 2015 Jul. Erratum in: J Natl Cancer Inst. 2017 Nov 1;109(11):.

8.

Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma.

Mhawech-Fauceglia P, Wang D, Samrao D, Godoy H, Ough F, Liu S, Pejovic T, Lele S.

Gynecol Oncol. 2012 Oct;127(1):198-201. doi: 10.1016/j.ygyno.2012.06.012. Epub 2012 Jun 15.

9.

Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.

Ricciardelli C, Lokman NA, Pyragius CE, Ween MP, Macpherson AM, Ruszkiewicz A, Hoffmann P, Oehler MK.

Oncotarget. 2017 Mar 14;8(11):17819-17832. doi: 10.18632/oncotarget.14867.

10.

SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.

Yang M, Xie X, Ding Y.

Oncol Rep. 2016 Mar;35(3):1796-806. doi: 10.3892/or.2016.4545. Epub 2016 Jan 5.

PMID:
26750614
11.

WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study.

Netinatsunthorn W, Hanprasertpong J, Dechsukhum C, Leetanaporn R, Geater A.

BMC Cancer. 2006 Apr 11;6:90.

12.

Immunohistochemical expression and prognostic relevance of Bmi-1, a stem cell factor, in epithelial ovarian cancer.

Abd El hafez A, El-Hadaad HA.

Ann Diagn Pathol. 2014 Apr;18(2):58-62. doi: 10.1016/j.anndiagpath.2013.11.004. Epub 2013 Nov 23.

PMID:
24342665
13.

Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.

Heeran MC, Høgdall CK, Kjaer SK, Christensen L, Jensen A, Blaakaer J, Christensen IJ, Høgdall EV.

APMIS. 2013 Dec;121(12):1177-86. doi: 10.1111/apm.12071. Epub 2013 Apr 18.

PMID:
23594232
14.

[Expression and promotor methylation of p73 gene in ovarian epithelial tumors].

Zhang YL, Guo XR, Shen DH, Cheng YX, Liang XD, Chen YX, Wang Y.

Zhonghua Bing Li Xue Za Zhi. 2012 Jan;41(1):33-8. Chinese.

PMID:
22455848
15.

Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.

Furlong F, Fitzpatrick P, O'Toole S, Phelan S, McGrogan B, Maguire A, O'Grady A, Gallagher M, Prencipe M, McGoldrick A, McGettigan P, Brennan D, Sheils O, Martin C, W Kay E, O'Leary J, McCann A.

J Pathol. 2012 Apr;226(5):746-55. doi: 10.1002/path.3035. Epub 2012 Jan 17. Erratum in: J Pathol. 2014 Feb;232(3):e1.

16.

Kindlin-2 inhibits serous epithelial ovarian cancer peritoneal dissemination and predicts patient outcomes.

Ren C, Du J, Xi C, Yu Y, Hu A, Zhan J, Guo H, Fang W, Liu C, Zhang H.

Biochem Biophys Res Commun. 2014 Mar 28;446(1):187-94. doi: 10.1016/j.bbrc.2014.02.087. Epub 2014 Feb 27.

PMID:
24583125
17.

Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells.

Park SH, Song JY, Kim YK, Heo JH, Kang H, Kim G, An HJ, Kim TH.

Int J Oncol. 2014 Mar;44(3):637-46. doi: 10.3892/ijo.2013.2232. Epub 2013 Dec 30.

18.

Over-Expression of TBL1XR1 Indicates Poor Prognosis of Serous Epithelial Ovarian Cancer.

Ma M, Yu N.

Tohoku J Exp Med. 2017 Mar;241(3):239-247. doi: 10.1620/tjem.241.239.

19.

Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer.

Elattar A, Warburton KG, Mukhopadhyay A, Freer RM, Shaheen F, Cross P, Plummer ER, Robson CN, Edmondson RJ.

Gynecol Oncol. 2012 Jan;124(1):142-7. doi: 10.1016/j.ygyno.2011.09.004. Epub 2011 Oct 15.

PMID:
22001143
20.

Validation of Revised FIGO Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum Based on a Single Histological Type.

Toptas T, Pestereli E, Erol O, Bozkurt S, Erdogan G, Simsek T.

Int J Gynecol Cancer. 2016 Jul;26(6):1012-9. doi: 10.1097/IGC.0000000000000736.

PMID:
27206284

Supplemental Content

Support Center